Combined Inhibition of SHP2 and CXCR1/2 Promotes Antitumor T-cell Response in NSCLC.
Animals
Antineoplastic Agents
/ pharmacology
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Cell Line, Tumor
Enzyme Inhibitors
/ pharmacology
Humans
Lung Neoplasms
/ drug therapy
Male
Mice
Mice, Inbred C57BL
Protein Tyrosine Phosphatase, Non-Receptor Type 11
/ antagonists & inhibitors
Receptors, Interleukin-8B
/ antagonists & inhibitors
Tumor Microenvironment
Xenograft Model Antitumor Assays
Journal
Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
20
03
2021
revised:
29
06
2021
accepted:
26
07
2021
pubmed:
7
8
2021
medline:
31
3
2022
entrez:
6
8
2021
Statut:
ppublish
Résumé
SHP2 inhibitors (SHP2i) alone and in various combinations are being tested in multiple tumors with overactivation of the RAS/ERK pathway. SHP2 plays critical roles in normal cell signaling; hence, SHP2is could influence the tumor microenvironment. We found that SHP2i treatment depleted alveolar and M2-like macrophages, induced tumor-intrinsic CCL5/CXCL10 secretion, and promoted B and T lymphocyte infiltration in
Identifiants
pubmed: 34353854
pii: 2159-8290.CD-21-0369
doi: 10.1158/2159-8290.CD-21-0369
pmc: PMC8758507
mid: NIHMS1730415
doi:
Substances chimiques
Antineoplastic Agents
0
CXCR2 protein, human
0
Enzyme Inhibitors
0
Receptors, Interleukin-8B
0
PTPN11 protein, human
EC 3.1.3.48
Protein Tyrosine Phosphatase, Non-Receptor Type 11
EC 3.1.3.48
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
47-61Subventions
Organisme : NCI NIH HHS
ID : P01 CA229086
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016087
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA252239
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA166480
Pays : United States
Organisme : NIH HHS
ID : S10 OD021747
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA049152
Pays : United States
Organisme : NCI NIH HHS
ID : R37 CA049152
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA248896
Pays : United States
Informations de copyright
©2021 The Authors; Published by the American Association for Cancer Research.
Références
Immunity. 2018 Apr 17;48(4):716-729.e8
pubmed: 29625895
Curr Opin Chem Biol. 2021 Jun;62:1-12
pubmed: 33418513
Nat Commun. 2020 Mar 26;11(1):1562
pubmed: 32218434
Trends Pharmacol Sci. 2019 Feb;40(2):128-141
pubmed: 30612715
Cancer Cell. 2019 Apr 15;35(4):559-572.e7
pubmed: 30905761
J Exp Med. 2021 Jan 4;218(1):
pubmed: 33045063
Nature. 2016 Jul 7;535(7610):148-52
pubmed: 27362227
Cancer Discov. 2020 Jan;10(1):54-71
pubmed: 31658955
Cancer Res. 2020 Nov 1;80(21):4840-4853
pubmed: 32928921
Nat Med. 2018 Jul;24(7):961-967
pubmed: 29808006
Nature. 2021 Jul;595(7868):578-584
pubmed: 34135508
Cancer Immunol Res. 2014 Jan;2(1):50-8
pubmed: 24778162
Cancer Cell. 2017 May 8;31(5):711-723.e4
pubmed: 28486109
Gastroenterology. 2010 Apr;138(4):1429-40
pubmed: 19909745
Sci Rep. 2021 Jan 14;11(1):1399
pubmed: 33446805
JCI Insight. 2020 May 21;5(10):
pubmed: 32324594
Cell. 2018 Dec 13;175(7):1731-1743.e13
pubmed: 30503213
BMC Bioinformatics. 2013 Apr 15;14:128
pubmed: 23586463
Cancer Res. 2017 Jun 1;77(11):2857-2868
pubmed: 28416485
Nature. 2020 Jan;577(7791):549-555
pubmed: 31942075
Nature. 2020 Jan;577(7791):556-560
pubmed: 31942077
Nat Protoc. 2010 May;5(5):929-34
pubmed: 20431538
Cancer Res. 2009 Apr 1;69(7):3077-85
pubmed: 19293190
Front Immunol. 2018 Nov 09;9:2456
pubmed: 30473691
Nat Immunol. 2016 Apr;17(4):422-32
pubmed: 26950239
Cancer Cell. 2016 Aug 8;30(2):194-196
pubmed: 27505669
Nature. 2020 Jan;577(7790):421-425
pubmed: 31915379
Immunity. 2007 Aug;27(2):281-95
pubmed: 17723218
Nat Rev Immunol. 2009 Mar;9(3):162-74
pubmed: 19197294
Nature. 2012 Mar 18;483(7391):613-7
pubmed: 22425996
PLoS One. 2014 Jul 10;9(7):e101881
pubmed: 25010215
Cancer Res. 2020 Jul 1;80(13):2889-2902
pubmed: 32350067
Nature. 2019 Nov;575(7781):217-223
pubmed: 31666701
J Immunol. 2015 Jun 1;194(11):5529-38
pubmed: 25911761
Cancer Discov. 2018 Oct;8(10):1237-1249
pubmed: 30045908
Cell. 2020 Sep 3;182(5):1232-1251.e22
pubmed: 32822576
Cell Mol Immunol. 2019 Jan;16(1):6-18
pubmed: 29628498
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
Nature. 2006 Apr 13;440(7086):890-5
pubmed: 16612374
Sci Rep. 2017 Jun 16;7(1):3698
pubmed: 28623253
Nat Immunol. 2021 Jan;22(1):53-66
pubmed: 33230330
Cancer Cell. 2019 Jun 10;35(6):885-900.e10
pubmed: 31185212
Infect Immun. 2013 Apr;81(4):1090-9
pubmed: 23340310
Cell. 2015 Jul 2;162(1):184-97
pubmed: 26095251
JCI Insight. 2019 Apr 4;4(7):
pubmed: 30944253
Immunity. 2019 Jun 18;50(6):1498-1512.e5
pubmed: 31097342
J Exp Med. 2008 Mar 17;205(3):625-40
pubmed: 18316415
Nature. 2020 Jan;577(7791):561-565
pubmed: 31942071
Nat Med. 2018 Jul;24(7):954-960
pubmed: 29808009
Sci Transl Med. 2020 Dec 2;12(572):
pubmed: 33268511
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Nature. 2016 May 25;534(7605):129-32
pubmed: 27251290
Nat Commun. 2020 Jun 2;11(1):2762
pubmed: 32488020
Cell. 2018 Dec 13;175(7):1744-1755.e15
pubmed: 30503208
Nat Immunol. 2018 Feb;19(2):108-119
pubmed: 29348500
Nucleic Acids Res. 2016 Jul 8;44(W1):W90-7
pubmed: 27141961
Nat Commun. 2016 Jul 06;7:12150
pubmed: 27381735
Cell. 2021 Dec 9;184(25):6101-6118.e13
pubmed: 34852236
Immunity. 2018 Mar 20;48(3):399-416
pubmed: 29562192
Curr Opin Immunol. 2013 Apr;25(2):200-5
pubmed: 23422836
Biochem Pharmacol. 2019 Apr;162:169-176
pubmed: 30414937
Cancer Discov. 2016 Mar;6(3):247-55
pubmed: 26715643
Nat Cell Biol. 2018 Sep;20(9):1064-1073
pubmed: 30104724
Immunity. 2019 May 21;50(5):1317-1334.e10
pubmed: 30979687
Nat Commun. 2021 Mar 5;12(1):1482
pubmed: 33674596
Nat Rev Immunol. 2019 Jun;19(6):369-382
pubmed: 30718830
Cell Mol Immunol. 2020 May;17(5):433-450
pubmed: 32238918
Nat Med. 2018 Jul;24(7):968-977
pubmed: 29808010
Annu Rev Immunol. 2013;31:227-58
pubmed: 23516982